Generation bio reports business highlights and fourth quarter and full year 2024 financial results

- company is applying its t cell-selective lipid nanoparticle to develop sirna therapeutics for t cell-driven autoimmune diseases

GBIO Ratings Summary

GBIO Quant Ranking